{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-050695","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2024-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.319392+00:00","generated_at":"2026-05-29T01:47:43.983405+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MIRA submits IND for Ketamir-2 (neuropathic pain) to FDA; Phase I expected Q1 2025","bullets":["IND submitted to FDA on Dec 19, 2024 for Ketamir-2, a novel oral ketamine analog.","Phase I clinical trials expected to start Q1 2025; Phase IIa planned for late 2025.","Preclinical data showed full pain reversal with no adverse safety findings.","Ketamir-2 targets unmet needs in neurological disorders and neuropathic pain."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-050695","json":"https://secwatch.observer/filing/0001493152-24-050695.json","markdown":"https://secwatch.observer/filing/0001493152-24-050695.md","text":"https://secwatch.observer/filing/0001493152-24-050695.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000149315224050695/0001493152-24-050695-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000149315224050695/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T01:47:43.983405+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}